Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.63 |
| ▸ | PPARA | Q07869 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.52 |
| ▸ | FABP2 | P12104 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304943 | 0.89 | MEN1 (0.65) | PPARDPPARAMEN1KMT2AMAPT | |
| SCHEMBL1304940 | 0.86 | PPARD (0.52) | PPARDPPARAMEN1KMT2ACYP1A2 | |
| SCHEMBL14999157 | 0.86 | GAA (0.54) | PPARDMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL3996186 | 0.85 | PPARD (0.49) | PPARDMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL14749238 | 0.85 | PPARD (0.49) | PPARDMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL11445258 | 0.84 | PPARD (0.58) | PPARDPPARAMEN1KMT2ACYP1A2 | |
| SCHEMBL29725091 | 0.83 | PPARD (0.48) | PPARDPPARAMEN1KMT2ACYP1A2 | |
| SCHEMBL3999379 | 0.83 | ALDH1A1 (0.54) | PPARDMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5138738 | 0.82 | PPARD (0.48) | PPARDPPARAMEN1KMT2AMAPT | |
| SCHEMBL2733042 | 0.81 | HSD17B10 (0.52) | CYP3A4GAATSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| CN-105348203-B | Inhibit the composition and method of JAK approach | 里格尔药品股份有限公司 | 2018-09-18 | — | — | CN | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-1904457-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006133426-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| CN-1070487-C | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2001-09-05 | — | — | CN | disclosed |
| EP-0609058-B1 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0394440-B1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1994-05-11 | — | — | EP | disclosed |
| US-4999378-A | Antilipemic, anticholesterol, antidiabetic, treatment of atherosclerosis and obesity | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0394440-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PPARD 3162/4885PPARA 3487/4885MEN1 3157/4885 |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PPARD 3162/4885PPARA 3487/4885MEN1 3157/4885 |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PPARD 3162/4885PPARA 3487/4885MEN1 3157/4885 |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PPARD 3162/4885PPARA 3487/4885MEN1 3157/4885 |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PPARD 3162/4885PPARA 3487/4885MEN1 3157/4885 |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | PPARD 3503/4885PPARA 4314/4885MEN1 2075/4885 |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PPARD 3162/4885PPARA 3487/4885MEN1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.